Expression of inflammatory cytokines in ovarian epithelial cancer and their correlation

Y J Tang; H T Dou; Q H Zhang; J J Liu; X S Yang

doi:10.54517/jbrha4336

Publication Frequency

Quarterly since 2025

Journal Articles

Search scope

Journal Center

Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

more

Volume Arrangement

2025

Vol 39, No 3 (2025)

Vol 39, No 2 (2025)

Vol 39, No 1 (2025)

Featured Articles

Macrophages in the pathogenesis of psoriasis and anti-psoriatic nanotherapies

Psoriasis is a common, chronic, and inflammatory skin disease. Macrophages account for about 61.3% of the inflammatory cells infiltrating psoriatic lesions. Modulating macrophage polarization, inhibiting their infiltration, and targeting the secretion of inflammatory factors and associated inflammatory pathways by these cells can alleviate psoriasis symptoms and inflammation. Moreover, nanomaterials as novel drug carriers, offer unique advantages such as large surface area, easy modification, high biocompatibility, good biodegradability, enhanced systemic adsorption, etc. Nanomaterials have great potential for efficient drug delivery and release, as well as improving therapeutic efficacy while reducing adverse effects. By systematically addressing the role of macrophages in psoriasis pathogenesis and the potential of nanomaterials in treating psoriasis through modulating macrophages, this review enhances our understanding of the disease mechanism and holds promise for novel therapeutic breakthroughs and advancements in the future treatment of psoriasis.

Expression of inflammatory cytokines in ovarian epithelial cancer and their correlation

Y J Tang, H T Dou, Q H Zhang, J J Liu, X S Yang

Article ID: 4336
Vol 31, Issue 2, 2017

DOI: https://doi.org/10.54517/jbrha4336

Received: 6 June 2022; Accepted: 6 June 2022; Available online: 6 June 2022; Issue release: 6 June 2022

Abstract

This study investigates the expression of interleukin (IL)-17 (IL-17A and IL-17D) and its role in ovarian epithelial tumor and its correlation with the clinical characteristics. Fifty malignant ovarian epithelial tumor specimens were collected after surgery and set as group A. Ten benign epithelioma specimens and ten normal epithelial specimens were set as group B and C, respectively. The expression of IL-17A and IL-17D in the three groups was detected using the EnVision method, and the correlation of positive expression rate with pathological type, clinical stage, presence of ascites and differentiation degree was analyzed. Group A had higher expression of IL-17A and IL-17D compared to group B and C (p less than 0.05). The expression rate was in correlation to clinical stage and differentiation degree, but in no correlation to pathological type and presence of ascites. The expression rate of malignant epithelioma in the early stage was lower than that in the late stage (p less than 0.05). Lower differentiation degree indicated higher expression rate (p less than 0.05). Pathological type and presence of ascites had no remarkable influence on the expression rate (p>0.05). Study of the expression of IL-17 provides theoretical support for the clinical treatment and prognosis prediction of ovarian epithelial tumor

Keywords

inflammatory cytokines;ovarian epithelial tumor;IL-17A;IL-17D;expression;correlation

References

Supporting Agencies

This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Editor-in-Chief

Dr. Fabio Malavasi

Medical Genetics, University of Torino Medical School, Italy

Co-Editor-in-Chief

Prof. Marcello Iriti

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy

Indexing & Archiving

News & Announcements

2025-02-01

Notice of Change in Publication Schedule

In addition to the first issue that has already been published by the original publisher, there will be four more issues released this year, with scheduled publication dates in March, June, September, and December respectively.

2025-01-21

Notice: Ownership Transfer of the Journal

Starting from Volume 39 Issue 2 (2025), the ownership of Journal of Biological Regulators and Homeostatic Agents (ISSN: 0393-974X (P); 1724-6083 (O)) will be transferred from Biolife Sas to Asia Pacific Academy of Science Pte. Ltd. As of 21 January 2025, authors should make submissions to the new journal system and follow the author guidelines. Asia Pacific Academy of Science Pte. Ltd. will take over the publication of manuscripts being processed.

More Announcements...